Skip to main content

Iran approves second Iranian-made COVID-19 vaccine

Iran's vaccine rollout has been marked by delays as the virus continues to spread rapidly across the country.
An Iranian health worker prepares an injection of the Iranian-made COVID-19 vaccine during the start of the second phase of trials in the capital, Tehran, on March 15, 2021.

Iran’s Health Ministry has approved a second domestically made COVID-19 vaccine for emergency use. The vaccine campaign in Iran has been relatively slow, and the country has been badly hit by the coronavirus. 

Iranian Health Minister Saeid Namaki said Tuesday that the Pasteur vaccine completed its third phase of clinical trials and received “permission for its emergency use.” The vaccine was developed in partnership with Cuban scientists, the state-owned Press TV reported.

The COVIran Barekat vaccine, also made in Iran, received emergency authorization last week, prompting Supreme Leader Ayatollah Ali Khamenei to take it.

The Islamic Republic has been among the countries worst affected by the pandemic in the Middle East. The country is registering around 10,000 new cases a day among its population of more than 80 million.

The vaccine rollout began in February for medical workers, but it has been hindered by a lack of supplies, long lines and crowded vaccine centers. This has left some people over the age of 70 who are eligible for the vaccine unable to receive it. The government has blamed the sluggish vaccine campaign on countries failing to deliver promised doses and international banking restrictions on Iran.

As of June 21, only 4.78% of Iranians had received one vaccine dose. The percentage increased significantly starting in late April but has since slowed, according to the Oxford University-based Our World in Data.

Iranian officials said on June 1 that a mass vaccine campaign for most of the population will begin in September. This constituted another delay.

Iran and Cuba have worked together to fight the virus throughout the pandemic. In addition to teaming up on the Pasteur vaccine, Cuba sent 100,000 doses of its Soberana vaccine to Iran in April for the third phase of its trial.

Join hundreds of Middle East professionals with Al-Monitor PRO.

Business and policy professionals use PRO to monitor the regional economy and improve their reports, memos and presentations. Try it for free and cancel anytime.

Already a Member? Sign in


The Middle East's Best Newsletters

Join over 50,000 readers who access our journalists dedicated newsletters, covering the top political, security, business and tech issues across the region each week.
Delivered straight to your inbox.


What's included:
Our Expertise

Free newsletters available:

  • The Takeaway & Week in Review
  • Middle East Minute (AM)
  • Daily Briefing (PM)
  • Business & Tech Briefing
  • Security Briefing
  • Gulf Briefing
  • Israel Briefing
  • Palestine Briefing
  • Turkey Briefing
  • Iraq Briefing

Premium Membership

Join the Middle East's most notable experts for premium memos, trend reports, live video Q&A, and intimate in-person events, each detailing exclusive insights on business and geopolitical trends shaping the region.

$25.00 / month
billed annually

Become Member Start with 1-week free trial
What's included:
Our Expertise AI-driven

Memos - premium analytical writing: actionable insights on markets and geopolitics.

Live Video Q&A - Hear from our top journalists and regional experts.

Special Events - Intimate in-person events with business & political VIPs.

Trend Reports - Deep dive analysis on market updates.

All premium Industry Newsletters - Monitor the Middle East's most important industries. Prioritize your target industries for weekly review:

  • Capital Markets & Private Equity
  • Venture Capital & Startups
  • Green Energy
  • Supply Chain
  • Sustainable Development
  • Leading Edge Technology
  • Oil & Gas
  • Real Estate & Construction
  • Banking

We also offer team plans. Please send an email to and we'll onboard your team.

Already a Member? Sign in

Start your PRO membership today.

Join the Middle East's top business and policy professionals to access exclusive PRO insights today.

Join Al-Monitor PRO Start with 1-week free trial